Sunesis Pharmaceuticals (SNSS)

[califax]

Catalent, Sunesis sign Phase 3 Valor clinical trial supply services agreement

Published: 25-Aug-2010

Catalent Pharma Solutions and Sunesis Pharmaceuticals have signed clinical supply services agreement to support Sunesis’ pivotal Phase 3 Valor trial of Vosaroxin in first relapse or primary refractory acute myeloid leukemia (AML).

Catalent is expected to provide expertise in labeling and kitting of the clinical trial materials to be used in Sunesis’ multinational trial, and will provide supply chain support to clinical sites.

Catalent said that as part of its development and clinical services segment, the clinical packaging and logistics will be handled in Catalent’s Philadelphia, PA and Schorndorf, Germany facilities.

Sunesis Pharma CEO Daniel Swisher said that as they continue to make important strides towards ensuring that the pivotal Phase 3 Valor trial is a well-executed study and work diligently on its timely launch, a key to their progress is their clinical supply partnership with Catalent Pharma Solutions.

Catalent clinical supply services vice president and general manager Frank Lis said that they were pleased to work with Sunesis in providing clinical supply services support for Vosaroxin and the Valor trial, and that they were confident that Catalent’s integrated solution will help Sunesis advance this important compound.

http://contractservices.pharmaceutical-business-review.com/news/catalent_sunesis_sign_phase_3_valor_clinical_trial_supply_services_agreement_100825/